Hemoptysis medical therapy

Hemoptysis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemoptysis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemoptysis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemoptysis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemoptysis medical therapy
CDC on Hemoptysis medical therapy
Hemoptysis medical therapy in the news
Blogs on Hemoptysis medical therapy
Directions to Hospitals Treating Hemoptysis
Risk calculators and risk factors for Hemoptysis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Hemoptysis is a symptom that indicates an underlying pulmonary or extrapulmonary cause. Pharmacologic medical therapy depends on an underlying cause. However, the mainstay of treatment for massive hemoptysis is supportive and surgical therapy.

Medical Therapy

• Hemoptysis is a symptom that indicates an underlying pulmonary or extrapulmonary cause.
• Pharmacologic medical therapy depends on an underlying cause.
• The mainstay of treatment for massive hemoptysis is supportive and surgical therapy.

Disease Name

• 1 Stage 1 - Massive hemoptysis
  • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
  • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
  • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
  • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days